Wilma Barcellini

12.1k total citations · 1 hit paper
320 papers, 6.2k citations indexed

About

Wilma Barcellini is a scholar working on Hematology, Physiology and Immunology. According to data from OpenAlex, Wilma Barcellini has authored 320 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 180 papers in Hematology, 136 papers in Physiology and 104 papers in Immunology. Recurrent topics in Wilma Barcellini's work include Erythrocyte Function and Pathophysiology (133 papers), Blood groups and transfusion (133 papers) and Blood disorders and treatments (54 papers). Wilma Barcellini is often cited by papers focused on Erythrocyte Function and Pathophysiology (133 papers), Blood groups and transfusion (133 papers) and Blood disorders and treatments (54 papers). Wilma Barcellini collaborates with scholars based in Italy, United States and United Kingdom. Wilma Barcellini's co-authors include Bruno Fattizzo, Alberto Zanella, Pier Luigi Meroni, Anna Zaninoni, Sigbjørn Berentsen, Juri Alessandro Giannotta, Elisa Fermo, Paola Bianchi, Agostino Cortelezzi and Cristina Vercellati and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Wilma Barcellini

292 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting

2019 286 citations Ulrich Jäger, Wilma Barcellini et al. profile →

Peers

Countries citing papers authored by Wilma Barcellini

Since Specialization

Citations

This map shows the geographic impact of Wilma Barcellini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wilma Barcellini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wilma Barcellini more than expected).

Fields of papers citing papers by Wilma Barcellini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wilma Barcellini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wilma Barcellini. The network helps show where Wilma Barcellini may publish in the future.

Co-authorship network of co-authors of Wilma Barcellini

This figure shows the co-authorship network connecting the top 25 collaborators of Wilma Barcellini. A scholar is included among the top collaborators of Wilma Barcellini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wilma Barcellini. Wilma Barcellini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open‐label study 2024 ·American Journal of Hematology ·Wilma Barcellini, Fabrizio Pane, Andrea Patriarca, (unknown), Louis Terriou, Maria T. DeSancho, Wahid T. Hanna, Lance Leopold, Erica Rappold, (unknown), (unknown), Ulrich Jäger	2
2	Iptacopan Monotherapy in Patients with Cold Agglutinin Disease: Phase II Study Results 2024 ·Blood ·Alexander Röth, Wilma Barcellini, (unknown), Shripad Chitnis, (unknown), Alessandra Vitaliti, Chi Chen, (unknown), (unknown), Hanny Al‐Samkari	1
3	Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study 2024 ·Blood ·Nichola Cooper, David J. Kuter, Henrik Frederiksen, (unknown), (unknown), Wilma Barcellini, Joan Cid, Catherine M. Broome, (unknown), Amitabha Mazumder, Alessandro Lucchesi, Xin Zhao, Antonio M. Risitano, Sangeeta Sawhney, Quentin A. Hill, Deepthi Jayawardene, (unknown), J. Zhao, Ahmed Daak	6
4	Diagnosis of Diamond-Blackfan anemia in adulthood: case series and review of the literature 2024 ·Orphanet Journal of Rare Diseases ·(unknown), Paola Bianchi, Elisa Fermo, Wilma Barcellini, Bruno Fattizzo	1
5	Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial 2024 ·Blood ·Caroline Piatek, Jong Wook Lee, Morag Griffin, J Nishimura, Christopher J. Patriquin, Hubert Schrezenmeier, Wilma Barcellini, Jamile M. Shammo, Anna Gayà, Mohammed H. Mahdi, (unknown), (unknown), Andrew Messali, Flore Sicre de Fontbrune, Jens Panse, Austin Kulasekararaj	1
6	Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up 2023 ·Blood Advances ·Alexander Röth, Catherine M. Broome, Wilma Barcellini, Tor Henrik Anderson Tvedt, Yoshitaka Miyakawa, Shirley D’Sa, David Cella, (unknown), Deepthi Jayawardene, (unknown), Frank Shafer, Marek Wardęcki, Ilene C. Weitz	8
7	Luspatercept in combination with recombinant erythropoietin in patients with myelodysplastic syndrome with ring sideroblasts: Stimulating early and late‐stage erythropoiesis 2023 ·European Journal Of Haematology ·Bruno Fattizzo, (unknown), (unknown), (unknown), Marta Riva, Wilma Barcellini	1
8	Molecular pharmacology in complement‐mediated hemolytic disorders 2023 ·European Journal Of Haematology ·(unknown), Wilma Barcellini, Bruno Fattizzo	14
9	Case report: Transfusion independence and abolition of extravascular hemolysis in a PNH patient treated with pegcetacoplan 2022 ·Frontiers in Immunology ·Bruno Fattizzo, (unknown), Anna Zaninoni, Anna Paola Marcello, Cristina Vercellati, (unknown), Wilma Barcellini	3
10	Intravascular hemolysis and multitreatment predict thrombosis in patients with autoimmune hemolytic anemia 2022 ·Journal of Thrombosis and Haemostasis ·Bruno Fattizzo, (unknown), Juri Alessandro Giannotta, Anna Zaninoni, Dario Consonni, Wilma Barcellini	27
11	Thrombopoietin receptor agonists in adult Evans syndrome: an international multicenter experience 2022 ·Blood ·Bruno Fattizzo, (unknown), (unknown), Giulio Giordano, Andrea Patriarca, Andreas Glenthøj, Silvia Cantoni, Marco Capecchi, (unknown), María Eva Mingot‐Castellano, Mariasanta Napolitano, Henrik Frederiksen, Tomás José González‐López, Wilma Barcellini	4
12	Autoimmune Hemolytic Anemia as a Complication of Congenital Anemias. A Case Series and Review of the Literature 2021 ·Journal of Clinical Medicine ·Irene Motta, Juri Alessandro Giannotta, (unknown), (unknown), Nicoletta Revelli, Giovanna Graziadei, Wilma Barcellini, Bruno Fattizzo	9
13	Comorbidities and complications in adults with pyruvate kinase deficiency 2020 ·European Journal Of Haematology ·Audra Boscoe, (unknown), Elizabeth Hedgeman, Eduard J. van Beers, Hanny Al‐Samkari, Wilma Barcellini, Stefan Eber, Bertil Glader, Hassan M. Yaish, Satheesh Chonat, Mukta Sharma, Kevin H.M. Kuo, Ellis J. Neufeld, Heng Wang, Madeleine Verhovsek, Sujit Sheth, Rachael F. Grace	17
14	Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives 2019 ·SHILAP Revista de lepidopterología ·Wilma Barcellini, Bruno Fattizzo, Anna Zaninoni	5
15	Results Update from the DRIVE PK Study: Effects of AG-348, a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency 2017 ·Blood ·Rachael F. Grace, D. Mark Layton, Frédéric Galactéros, Christian Rosé, Wilma Barcellini, D. Holmes Morton, Eduard J. van Beers, Hassan M. Yaish, Yaddanapudi Ravindranath, Kevin H.M. Kuo, Sujit Sheth, Janet L. Kwiatkowski, Bruce A. Silver, Charles Kung, Marvin B. Cohen, Hua Yang, Penelope A. Kosinski, Lei Hua, Ann Barbier, Bertil Glader	2
16	Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors 2012 ·Clinical Cancer Research ·Carlo Visco, Francesco Maura, Giacomo Tuana, Luca Agnelli, Marta Lionetti, Sonia Fabris, Elisabetta Novella, Ilaria Giaretta, Gianluigi Reda, Wilma Barcellini, Luca Baldini, Antonino Neri, Francesco Rodeghiero, Agostino Cortelezzi	20
17	Diagnostic power of laboratory tests for hereditary spherocytosis: a comparison study in 150 patients grouped according to molecular and clinical characteristics 2011 ·Haematologica ·Paola Bianchi, Elisa Fermo, Cristina Vercellati, Anna Paola Marcello, Laura Porretti, Agostino Cortelezzi, Wilma Barcellini, Andréa Zanella	125
18	Effetto di pidotimod sulle funzioni del sistema immunitario umani : studio in vitro ed ex vivo 1993 ·María Orietta Borghi, (unknown), (unknown), Vincenzo Carbonelli, Wilma Barcellini, Nicoletta Del Papa, L. La Rosa, (unknown), Donatella Gambini, Pier Luigi Meroni	2
19	Synergisms between different activation pathways in adult and aged human lymphocytes. 1989 ·PubMed ·María Orietta Borghi, Wilma Barcellini, (unknown), (unknown), Pier Luigi Meroni	1
20	Effect of long-term treatment with bacillus subtilis on the frequency of urinary tract infections in older patients 1983 ·Pier Luigi Meroni, (unknown), Wilma Barcellini	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact